NO960049L - Fremstilling og stabilisering av celler - Google Patents

Fremstilling og stabilisering av celler

Info

Publication number
NO960049L
NO960049L NO960049A NO960049A NO960049L NO 960049 L NO960049 L NO 960049L NO 960049 A NO960049 A NO 960049A NO 960049 A NO960049 A NO 960049A NO 960049 L NO960049 L NO 960049L
Authority
NO
Norway
Prior art keywords
preparation
cells
stabilization
stabilized
stabilized cell
Prior art date
Application number
NO960049A
Other languages
English (en)
Norwegian (no)
Other versions
NO960049D0 (no
Inventor
Vivian Granger
David Barnett
John Tennison Reilly
Petra Susanne Maria Mayr
Shawn Patrick Fay
Original Assignee
North Gen Hospital Nhs Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939313962A external-priority patent/GB9313962D0/en
Priority claimed from GB9406698A external-priority patent/GB9406698D0/en
Application filed by North Gen Hospital Nhs Trust filed Critical North Gen Hospital Nhs Trust
Publication of NO960049D0 publication Critical patent/NO960049D0/no
Publication of NO960049L publication Critical patent/NO960049L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002—Partitioning blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Ecology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO960049A 1993-07-05 1996-01-05 Fremstilling og stabilisering av celler NO960049L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939313962A GB9313962D0 (en) 1993-07-05 1993-07-05 Preparation and stabilisation of leucocytes
GB939315871A GB9315871D0 (en) 1993-07-05 1993-07-20 Preparation and stabilisation of leucocytes
GB9406698A GB9406698D0 (en) 1994-04-05 1994-04-05 Preparation and stabilisation of cell suspensions
PCT/EP1994/002189 WO1995001796A1 (en) 1993-07-05 1994-07-05 Preparation and stabilisation of cells

Publications (2)

Publication Number Publication Date
NO960049D0 NO960049D0 (no) 1996-01-05
NO960049L true NO960049L (no) 1996-03-05

Family

ID=27266764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960049A NO960049L (no) 1993-07-05 1996-01-05 Fremstilling og stabilisering av celler

Country Status (14)

Country Link
US (2) US6197540B1 (de)
EP (1) EP0708649B1 (de)
JP (1) JPH09503051A (de)
AT (1) ATE241368T1 (de)
AU (2) AU700699B2 (de)
BR (1) BR9407003A (de)
CA (1) CA2166729A1 (de)
DE (2) DE69432751T2 (de)
ES (1) ES2197168T3 (de)
FI (1) FI960045A7 (de)
GB (1) GB2279653B (de)
NO (1) NO960049L (de)
NZ (1) NZ271318A (de)
WO (1) WO1995001796A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0708649B1 (de) 1993-07-05 2003-05-28 Sheffield Teaching Hospitals National Health Service Trust Präparation und stabilisation von zellen
EP0754301B1 (de) * 1994-04-05 1998-09-09 Northern General Hospital N.H.S. Trust Herstellung und stabilisierung von zellsuspensionen
GB2313288B (en) * 1996-05-24 2000-07-12 North Gen Hospital Nhs Trust Specimen collection fluid
EP1182457A1 (de) * 2000-08-17 2002-02-27 Mallinckrodt Baker B.V. Verfahren und Reagens zur Analyse von Blutproben, im besonderen für tierärztliche Anwendungen
US6913932B2 (en) * 2002-08-23 2005-07-05 Beckman Coulter, Inc. Formaldehyde-ammonium salt complexes for the stabilization of blood cells
CA2445204C (en) * 2002-10-16 2014-08-12 Streck Laboratories, Inc. Method and device for collecting and preserving cells for analysis
US7267980B1 (en) 2003-04-04 2007-09-11 Research & Diagnostic Systems, Inc. Stabilizing solution for cells and tissues
US20050085028A1 (en) * 2003-10-21 2005-04-21 International Business Machines Corporation Method and structure to suppress external latch-up
CN100376669C (zh) * 2005-02-25 2008-03-26 深圳迈瑞生物医疗电子股份有限公司 生物红细胞体积长期稳定的处理方法
US20070015134A1 (en) * 2005-07-15 2007-01-18 Beckman Coulter, Inc. Quantitative stabilized cell reference control products and methods
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
CA2730191C (en) * 2008-07-11 2018-06-19 Secretary Of State For Health Stimulated cell standards
US20100167271A1 (en) * 2008-12-30 2010-07-01 Streck, Inc. Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
US8304187B2 (en) 2009-02-18 2012-11-06 Streck, Inc. Preservation of cell-free RNA in blood samples
US20110111410A1 (en) * 2009-11-09 2011-05-12 Streck, Inc. Stabilization of rna in intact cells within a blood sample
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12655483B2 (en) 2010-05-18 2026-06-16 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
EP2854058A3 (de) 2010-05-18 2015-10-28 Natera, Inc. Verfahren zur nichtinvasiven pränatalen Ploidiezuordnung
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
AU2011348100B2 (en) 2010-12-22 2016-08-25 Natera, Inc. Methods for non-invasive prenatal paternity testing
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
EP2704740B1 (de) 2011-05-04 2016-10-05 Streck, Inc. Inaktiviertes schweinegrippe-virus und verfahren zu seiner herstellung
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
EP3024323B1 (de) 2013-07-24 2022-10-19 Streck, Inc. Zusammensetzungen und verfahren zur stabilisierung zirkulierender tumorzellen
RU2717641C2 (ru) 2014-04-21 2020-03-24 Натера, Инк. Обнаружение мутаций и плоидности в хромосомных сегментах
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
EP4428863A3 (de) 2015-05-11 2024-12-11 Natera, Inc. Verfahren und zusammensetzungen zur bestimmung der ploidie
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
JP7280044B2 (ja) 2016-04-15 2023-05-23 ナテラ， インコーポレイテッド 肺癌の検出方法
EP3491381B1 (de) 2016-07-29 2025-09-24 Streck LLC Suspensionszusammensetzung zur kontrolle einer hämatologischen analyse
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
WO2018136751A1 (en) 2017-01-22 2018-07-26 Chryos, Llc Composition and method of use of the same for preserving cells for analysis
JP7293244B2 (ja) 2017-10-19 2023-06-19 ストレック， インコーポレイテッド 溶血、凝固調節および細胞外小胞の安定化のための組成物
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
EP3737773B1 (de) 2018-01-12 2023-04-12 Natera, Inc. Neuartige primer und verwendungen davon
DK3781714T3 (da) 2018-04-14 2026-03-30 Natera Inc Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna
WO2019210306A1 (en) * 2018-04-27 2019-10-31 Momenta Pharmaceuticals , Inc. Blood preparation
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system
CN113325171B (zh) * 2021-08-02 2021-12-21 天津康博尔生物基因技术有限公司 检测人体红细胞叶酸含量的试剂盒、检测方法及用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1068862B (de) 1957-05-03 1959-11-12 Penicillin-Gesellschaft Dauelsberg a Co., Göttingen Verfahren zur Verlängerung der Haltbarkeit von Blutkonserven
DE1147004B (de) 1959-10-16 1963-04-11 Dr Med Herbert Fischer Verfahren zur Konservierung von lebenden menschlichen oder tierischen Zellpraeparaten, insbesondere von Blut und Blutbestandteilen
CA933092A (en) 1969-04-10 1973-09-04 V. Collins Zeola Method of prolonging the viability of lymphocytes
FR2202688B1 (de) 1972-10-17 1977-04-15 Cepbepe
US4045488A (en) 1974-11-06 1977-08-30 Pfizer Inc. Aminophenyltetralin compounds
IT1065125B (it) 1975-08-20 1985-02-25 Boehringer Mannheim Gmbh Processo per mantenere costante l attivita di fosfatasi alcalina e siero di controllo contenente tale fosfatasi
DE2551208C3 (de) * 1975-11-14 1981-05-27 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer stabilen Erythrozyten-Präparation
US4040785A (en) 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
US4152208A (en) 1977-03-29 1979-05-01 Hoffmann-La Roche Inc. Stabilized leucocytes
DE2828820A1 (de) 1977-08-01 1979-02-08 Warner Lambert Co Verfahren zur herstellung einer stabilen blutplaettchensuspension und nach dem verfahren erhaltene stabile blutplaettchensuspension
US4302355A (en) * 1977-08-01 1981-11-24 Warner-Lambert Company Platelet reference control
US4324687A (en) 1979-02-15 1982-04-13 Louderback Allan Lee Blood biochemistry control standard
DE2949824A1 (de) 1979-12-12 1981-07-02 Marianne Dr. 5000 Köln Sehrbundt Verfahren zur stabilisierung von lymphozyten/thrombozytennmischsuspensionen
US4346018A (en) * 1980-06-16 1982-08-24 Coulter Electronics, Inc. Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes
US4405719A (en) * 1981-05-29 1983-09-20 Coulter Electronics, Inc. Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures
US4704352A (en) 1985-06-25 1987-11-03 Baxter Travenol Laboratories, Inc. L-ascorbate-2-phosphate salts in blood cell storage
JPH06100606B2 (ja) 1985-08-08 1994-12-12 リス、エ−ベルハルト 採取血中のグルコース含量の低減防止法
US4675185A (en) 1985-12-06 1987-06-23 Baxter Travenol Laboratories, Inc. Solution for stabilizing red blood cells during storage
US4729959A (en) 1986-02-24 1988-03-08 Streck Laboratories, Inc. Glucose reference control for glucose test strips
US4806343A (en) 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
IT1188132B (it) * 1986-05-07 1987-12-30 Fameccanica Spa Procedimento e dispositivo per la produzione di film perforati particolarmente film perforati di materiale plastico per articoli igienico sanitari
US5250438A (en) 1990-05-09 1993-10-05 Streck Laboratories, Inc. Method for differential determination of white blood cells using diazolidinyl urea to stabilize white blood cells
SU1767436A1 (ru) 1990-05-22 1992-10-07 Черновицкий Государственный Университет Способ определени глюкозы в крови
US5260048A (en) 1991-05-08 1993-11-09 Streck Laboratories, Inc. Tissue fixative solution and method
US5270208A (en) * 1991-05-09 1993-12-14 Streck Laboratories, Inc. White blood cell hematology control
JPH0820452B2 (ja) 1991-12-16 1996-03-04 株式会社いかがく 血液中糖類の微生物による消費阻止方法
US5422277A (en) * 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
WO1993021928A1 (en) 1992-04-24 1993-11-11 Streck Laboratories, Inc. Liquid glucose control solution and process of making the same
US5407794A (en) * 1992-09-08 1995-04-18 Cytocolor Inc. Oxazine stained lymphocytes and method
CA2123227C (en) 1992-09-10 2009-04-28 Wayne L. Ryan Method and composition for preserving antigens and process for utilizing cytological material produced by same
FR2705359B1 (fr) * 1993-05-19 1995-08-18 Immunotech Sa Méthode de protection des cellules leucocytaires, composition protectrice, composition de sang protégée, et méthode d'analyse sanguine.
EP0708649B1 (de) 1993-07-05 2003-05-28 Sheffield Teaching Hospitals National Health Service Trust Präparation und stabilisation von zellen
EP0754301B1 (de) 1994-04-05 1998-09-09 Northern General Hospital N.H.S. Trust Herstellung und stabilisierung von zellsuspensionen

Also Published As

Publication number Publication date
AU4441096A (en) 1996-06-06
GB2279653A (en) 1995-01-11
DE708649T1 (de) 2001-09-20
GB2279653B (en) 1998-02-11
WO1995001796A1 (en) 1995-01-19
FI960045L (fi) 1996-01-05
DE69432751T2 (de) 2004-04-29
FI960045A0 (fi) 1996-01-05
AU7490994A (en) 1995-02-06
GB9413558D0 (en) 1994-08-24
FI960045A7 (fi) 1996-01-05
JPH09503051A (ja) 1997-03-25
BR9407003A (pt) 1996-03-26
EP0708649B1 (de) 2003-05-28
DE69432751D1 (de) 2003-07-03
US6197539B1 (en) 2001-03-06
AU700699B2 (en) 1999-01-14
EP0708649A1 (de) 1996-05-01
NZ271318A (en) 1998-08-26
ATE241368T1 (de) 2003-06-15
CA2166729A1 (en) 1995-01-19
ES2197168T3 (es) 2004-01-01
US6197540B1 (en) 2001-03-06
NO960049D0 (no) 1996-01-05

Similar Documents

Publication Publication Date Title
ES2122589T3 (es) Preparacion y estabilizacion de suspensiones celulares.
AU6056194A (en) Substituted mono- and bipyridylmethylpyridones
AU4441096A (en) Preparation and stabilisation of cells
AU6667594A (en) Solid, glyme-containing electrolytes including ion salt derivatives and electrolytic cells produced thereform
NO871729L (no) Fremgangsmaate for aa frembringe paasproeytede belegg, apparat for gjennomfoering av fremgangsmaaten og gjenstander tilvirket i samsvar med fremgangsmaaten.
DK473987A (da) Fremgangsmaade til kontinuert produktion af et oensket heterologt protein i en eukaryotisk vaertcelle, vektor, som tilfoerer denne evne, og celler transformeret med vektoren
HU905605D0 (en) Substituted imidazoles
CA2148928A1 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
MY129973A (en) Sulphonylbenzyl-substituted pyridones.
IE800102L (en) N-benzylimidazoles
WO1996003515A3 (en) Surface expression of enzyme in gene directed prodrug therapy
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
GR930300079T1 (en) Benzoic acid substituted derivatives having cardiovascular activity.
WO1998037185A3 (en) Vectors for controlled gene expression
EP0342034A3 (de) Verfahren zur Haarfärbung durch die aufeinanderfolgende Applikation einer Metallionen enthaltenden Zusammensetzung und einer eine 5,6-dihydroxy-2-karbonsäure enthaltenden Zusammensetzung
AU2844889A (en) Method for suppressing the growth of normal and cancer cells
AU4157685A (en) Immunosuppressant factor
CA2199832A1 (en) Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
CA2227241A1 (en) Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
AU7938294A (en) Method for controlled modification of enzymes, enzymes modified in this way and the use of such enzymes
AU7226391A (en) Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess
AU673414B2 (en) Cathodic active material composition for dry cells, method for preparing the same, and alkaline battery
NO894008D0 (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
AU2885992A (en) Strains of the trichoderma fungus, fungicide derived therefrom and process for using the same
WO1993005807A3 (en) Erythropoietin potentiating agents and methods for their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application